FibroMAX: towards a new universal biomarker of liver disease? (Q36950410)

17 August 2017

1 reference

title

FibroMAX: towards a new universal biomarker of liver disease? (English)

1 reference

17 August 2017

0 references

Françoise Imbert-Bismut

3

object named as

Françoise Imbert-Bismut

0 references

Thierry Poynard

object named as

Thierry Poynard

6

0 references

Mona Munteanu

2

object named as

Mona Munteanu

1 reference

17 August 2017

5

Vlad Ratziu

1 reference

17 August 2017

4

Djamila Messous

1 reference

17 August 2017

1

Rachel Morra

1 reference

17 August 2017

author name string

Françoise Imbert-Bismut

3

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

481-490

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

17 August 2017

1 reference

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

A novel panel of blood markers to assess the degree of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Comparative study of two models that use biochemical parameters for the non-invasive diagnosis of fibrosis in patients with hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Performance of serum marker panels for liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Noninvasive prediction of fibrosis in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.481

21 January 2018

Identifiers

DOI

10.1586/14737159.7.5.481

1 reference

17 August 2017

1 reference